Eli Lilly and Company - Stock Based Compensation

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Millions.

The item "Stock-Based-Compensation" stands at 631.80 Million United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

Eli Lilly and Company's third quarter result of 151.10 Million USD for the item "Stock Based Compensation" represents a decrease of -18.37 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 151.10 Million USD for the item "Stock Based Compensation" represents an increase of 13.44 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 631.80 Million USD for the item "Stock Based Compensation" represents an increase of 2.92 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 7.90 Million United States Dollars compared to the value the year prior.
The 1 year change is 7.90 Million United States Dollars.
The 3 year change is 278.30 Million United States Dollars.
The 5 year change is 329.90 Million United States Dollars.
The 10 year change is 431.80 Million United States Dollars.

The Serie's long term average value is 310.89 Million United States Dollars. It's latest available value, on 09/30/2025, is 320.91 Million United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 09/30/2012, to it's latest available value, on 09/30/2025, is +642.20 Million.
The Serie's change in United States Dollars from it's maximum value, on 06/30/2024, to it's latest available value, on 09/30/2025, is -74.50 Million.